Three fast-growing niche players backed by Ashish Kacholia have posted over 20% profit growth—but pricey valuations raise questions. Should they be on your watchlist?

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Sun Pharmaceutical Industries Ltd. closed 14.78% below its 52-week high of 1,960.20 rupees, which the company achieved on ...

Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

India's pharma sector is poised for innovation-led growth, fueled by patent expirations and government support. The ₹5,000-cr ...

Corona Remedies Limited appoints four independent directors with diverse expertise in pharmaceutical formulation and ...

ProPublica spent 14 months investigating the FDA’s oversight of foreign drugmakers that send medications to the U.S. These ...

Jammu: In a special drive aimed at curbing the misuse of pharmaceuticals with habit forming ingredients, authorities in Jammu ...